Big Pharma Insiders Pessimistic About Pricing Going Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing and market access continue to be trends that plague big pharma, even as patent expirations and lagging new drug launches create harder circumstances for companies.